JPH04154795A - Separation of steroid compound - Google Patents
Separation of steroid compoundInfo
- Publication number
- JPH04154795A JPH04154795A JP2278614A JP27861490A JPH04154795A JP H04154795 A JPH04154795 A JP H04154795A JP 2278614 A JP2278614 A JP 2278614A JP 27861490 A JP27861490 A JP 27861490A JP H04154795 A JPH04154795 A JP H04154795A
- Authority
- JP
- Japan
- Prior art keywords
- separation
- group
- separating
- polysaccharide
- skeleton
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 steroid compound Chemical class 0.000 title claims description 17
- 238000000926 separation method Methods 0.000 title abstract description 42
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 30
- 239000005017 polysaccharide Substances 0.000 claims abstract description 30
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 20
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 150000004676 glycans Chemical class 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 abstract description 26
- 238000004587 chromatography analysis Methods 0.000 abstract description 12
- 125000001424 substituent group Chemical group 0.000 abstract description 8
- 125000001931 aliphatic group Chemical group 0.000 abstract description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 abstract description 2
- 150000001719 carbohydrate derivatives Chemical class 0.000 abstract 1
- 150000001720 carbohydrates Chemical group 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000002345 steroid group Chemical group 0.000 abstract 1
- 230000003637 steroidlike Effects 0.000 abstract 1
- 150000004804 polysaccharides Chemical class 0.000 description 27
- 150000003431 steroids Chemical group 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 9
- 230000014759 maintenance of location Effects 0.000 description 9
- 238000010828 elution Methods 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000002245 particle Substances 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- SBTVLCPCSXMWIQ-UHFFFAOYSA-N (3,5-dimethylphenyl) carbamate Chemical compound CC1=CC(C)=CC(OC(N)=O)=C1 SBTVLCPCSXMWIQ-UHFFFAOYSA-N 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 229920001503 Glucan Polymers 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 1
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- YJDYCULVYZDESB-HKQXQEGQSA-N (5r,8r,9s,10s,13s,14s)-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-one Chemical compound C1CCC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 YJDYCULVYZDESB-HKQXQEGQSA-N 0.000 description 1
- VMNRNUNYBVFVQI-QYXZOKGRSA-N (5s,8s,9s,10s,13s,14s)-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one Chemical compound C([C@@H]1CC2)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CCC[C@@]2(C)CC1 VMNRNUNYBVFVQI-QYXZOKGRSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- PUMRUSBKNSBTAL-UHFFFAOYSA-N 3,4-dihydro-2h-chromene-2-carbaldehyde Chemical compound C1=CC=C2OC(C=O)CCC2=C1 PUMRUSBKNSBTAL-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920002558 Curdlan Polymers 0.000 description 1
- 239000001879 Curdlan Substances 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- 101000633503 Homo sapiens Nuclear receptor subfamily 2 group E member 1 Proteins 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 241000575946 Ione Species 0.000 description 1
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 101000650578 Salmonella phage P22 Regulatory protein C3 Proteins 0.000 description 1
- 229920002305 Schizophyllan Polymers 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical group C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 101001040920 Triticum aestivum Alpha-amylase inhibitor 0.28 Proteins 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WQZGKKKJIJFFOK-RWOPYEJCSA-N beta-D-mannose Chemical compound OC[C@H]1O[C@@H](O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-RWOPYEJCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 229940078035 curdlan Drugs 0.000 description 1
- 235000019316 curdlan Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920005640 poly alpha-1,3-glucan Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007151 ring opening polymerisation reaction Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明はステロイド骨格を有する構造類似の化合物、特
に異性体の混合物を分離することにより、各々の異性体
を純品として得る方法に関するものである。[Detailed Description of the Invention] [Industrial Application Field] The present invention relates to a method of separating structurally similar compounds having a steroid skeleton, particularly a mixture of isomers, to obtain each isomer as a pure product. be.
ステロイド骨格を有する化合物は、生体中にあまねく存
在し、副腎皮質ホルモン、性ホルモン等として強い生理
活性を示すものが少なくない。Compounds having a steroid skeleton are ubiquitous in living organisms, and many of them exhibit strong physiological activity as adrenal cortical hormones, sex hormones, and the like.
医薬としてこれを合成する場合には、天然に多量に存在
する安価なステロイド化合物を前駆体として、化学変換
によって目的物に導く場合が多い。しかしながら、この
化学変換において分離の困難な異性体を副生ずることが
少なくない。またそれら異性体の混合比を正確に求める
ことすら難しい場合がある。When synthesizing this as a medicine, it is often the case that a naturally abundant and inexpensive steroid compound is used as a precursor and the target product is led through chemical conversion. However, this chemical conversion often produces by-product isomers that are difficult to separate. Furthermore, it may be difficult to even accurately determine the mixing ratio of these isomers.
構造の似通った物質を分離、分析するための方法として
有力なものにクロマトグラフィー法がある。クロマトグ
ラフィー法においてはシリカゲルや炭化水素基を結合し
たシリカゲル(所謂005)などの分離剤を用い、これ
らに対する吸着あるいは分配の比率が、物質によって異
なることを利用して分離する。Chromatography is a powerful method for separating and analyzing substances with similar structures. In the chromatography method, a separation agent such as silica gel or silica gel bonded with a hydrocarbon group (so-called 005) is used, and separation is performed by taking advantage of the fact that the adsorption or distribution ratio to these agents differs depending on the substance.
〔発明が解決しようとする課題]
しかしながら、このような方法を用いても、なおかつ構
造の酷領した異性体の分離は著しく困難であることが少
なくない。ステロイド骨格を有する構造類似の化合物、
特に異性体も例外ではない。[Problems to be Solved by the Invention] However, even when such a method is used, it is often extremely difficult to separate isomers with severely deformed structures. Structurally similar compounds with steroid skeletons,
In particular, isomers are no exception.
従って本発明の目的は、ステロイド骨格を有する化合物
、特に異性体の効果的な分離、分析の方法を提供するこ
とにあり、かかる方法が確立されれば、例えば医薬品の
製造、代謝の研究等への利用が期待される。Therefore, an object of the present invention is to provide a method for effective separation and analysis of compounds having steroid skeletons, especially isomers. is expected to be used.
本発明者らは前述したステロイド骨格を有する化合物を
分離、分析することの重要性に鑑み、それらをより効果
的に分離することのできる分離剤を見出すべく鋭意検討
を重ねた。In view of the importance of separating and analyzing the aforementioned compounds having steroid skeletons, the present inventors have conducted extensive studies in order to find a separating agent that can more effectively separate them.
その結果、多糖の誘導体を有効成分とする吸着剤を利用
した分離方法がステロイド骨格を有する化合物の異性体
の分離に適していることを見出し、本発明を完成するに
至った。As a result, the present inventors discovered that a separation method using an adsorbent containing a polysaccharide derivative as an active ingredient is suitable for separating isomers of compounds having a steroid skeleton, and completed the present invention.
即ち、本発明は、ステロイド骨格を有する化合物を分離
する方法に於いて、多糖誘導体を有効成分とする分離剤
を用いることを特徴とするステロイド化合物の分離法に
関するものである。That is, the present invention relates to a method for separating steroid compounds, which is characterized in that a separation agent containing a polysaccharide derivative as an active ingredient is used in the method for separating compounds having a steroid skeleton.
本発明に言うステロイド骨格を有する化合物とは下式に
示ずA、 B、 Cの六員環とDの五員環とが縮合した
基本骨格を有するものである。The compound having a steroid skeleton according to the present invention is shown in the following formula and has a basic skeleton in which six-membered rings A, B, and C and a five-membered ring D are condensed.
天然に得られるステロイドには、17−β−位にアルキ
ル基、10−β−,13−β−位にメチル基を、5位に
二重結合、3位にオキソあるいはオキシ基を有すること
が多いが、その他、多様な構造をとる。本発明が分離の
対象とする化合物とは天然、合成の別を問わず、上記基
本骨格上の置換基の有無及び位置(その立体化学も含め
て)、不飽和結合の有無及び位置、もしくは環縮合の立
体化学(cisかtransか)等の相違に基づいて生
じる構造的相違を持つ化合物を意味する。特にこれらが
異性体である場合に、更には立体異性体である場合に、
分離の困難なケースが多く、従って本発明の重要性は大
きい。Naturally obtained steroids may have an alkyl group at the 17-β-position, a methyl group at the 10-β- and 13-β-positions, a double bond at the 5-position, and an oxo or oxy group at the 3-position. There are many, but they also take on a variety of other structures. The compounds to be separated by the present invention are the presence or absence and position of substituents (including their stereochemistry) on the basic skeleton, the presence or absence and position of unsaturated bonds, or rings, regardless of whether they are natural or synthetic. It refers to compounds with structural differences caused by differences in condensation stereochemistry (cis or trans), etc. Especially when these are isomers, and even stereoisomers,
There are many cases where separation is difficult, and therefore the present invention is of great importance.
本発明に用いられる分離剤は多糖の誘導体を有効成分と
するものである。ここでいう多糖とは合成多糖、天然多
糖、天然物変成多糖のいずれかは問わず、環上に1個以
上の水酸基もしくはアミノ基を有するテトラヒドロフラ
ンあるいはテトラヒドロピラン環がアセタール或いはケ
タール結合を介して複数個結合したものである。The separating agent used in the present invention contains a polysaccharide derivative as an active ingredient. The term polysaccharide here refers to synthetic polysaccharides, natural polysaccharides, or modified natural polysaccharides, in which multiple tetrahydrofuran or tetrahydropyran rings having one or more hydroxyl or amino groups on the ring are linked via acetal or ketal bonds. It is a combination of individual parts.
天然に得られる多糖を例示するなら、セルロース、アミ
ロース、シクロデキストリン、β−1,4−キトサン、
キチン、β−1,4−マンナン、β−1,4−キシラン
、イヌリン、α−1,3−グルカン、β−1,3−グル
カン(所謂カードラン、シゾフィラン等)、β−1,2
−グルカン、アガロース、グルコマンナン、β−1,2
−グルカン、プルラン等である。近年ではこの多糖の範
晴に入るものが二環アセクールの開環重合等の手法で得
られている。これら多糖の中でも、一種乃至二種の糖残
基が規則的に結合したものが好ましく、分子内の糖残基
数は数平均にして2以上のものが好ましい。Examples of naturally occurring polysaccharides include cellulose, amylose, cyclodextrin, β-1,4-chitosan,
Chitin, β-1,4-mannan, β-1,4-xylan, inulin, α-1,3-glucan, β-1,3-glucan (so-called curdlan, schizophyllan, etc.), β-1,2
-Glucan, agarose, glucomannan, β-1,2
-Glucan, pullulan, etc. In recent years, polysaccharides that fall into this category have been obtained by methods such as ring-opening polymerization of two-ring acecur. Among these polysaccharides, polysaccharides in which one or two types of sugar residues are regularly bonded are preferred, and the number of sugar residues in the molecule is preferably two or more on average.
多糖の誘導体とは、上記多糖の有する水酸基、あるいは
アミノ基上の一個の水素原子の一部あるいは全部、好ま
しくは70%以上を他の原子団で置換したものである。A polysaccharide derivative is one in which part or all, preferably 70% or more, of one hydrogen atom on the hydroxyl group or amino group of the polysaccharide has been replaced with another atomic group.
ここでいう原子団としては、
で表される基が挙げられ、R1は炭素数1乃至3より成
る脂肪族基、炭素数3乃至8より成る環式脂肪族基、炭
素数4乃至20より成る芳香族基、芳香脂肪族基(アラ
ルキル基)、もしくはヘテロ芳香族基であり、いずれも
置換基を有しても良い。上記の基のうち、主要なものを
例示するなら、アセチル基、プロピオニル基、フェニル
アセチル基、フェノキシアセチル基、光学活性あるいは
ラセミンクなα−フェニルプロピオニル基、ベンゾイル
基、ナフトイル基及びそれらの芳香環上にメチル、クロ
ルフェニルその他の置換基を−乃至複数個有するもの、
メチルカルバモイル基、フェニルカルバモイル基、ナフ
チルカルバモイル基、ヘンシルカルバモイル基、ナフチ
ルメチルカルバモイル基、光学活性もしくはラセミンク
なα−フェニルエチル基、α−ナフチルエチル基、及び
それらの芳香環上にメチル、クロル、フェニルその他の
置tagを−乃至複数個有するもの、ベンジル基、ナフ
チルメチル基、及びそれらの芳香環上にメチル、クロル
、フェニルその他の置換基を−乃至複数個有するもの、
メチル基、エチル基、プロピル基、2−ヒドロキシエチ
ル基、2−ヒドロキシ−2−メチルプロピル基、光学活
性あるいはラセミンクな2−ヒドロキシプロピル基など
である。Examples of the atomic group here include a group represented by the following, where R1 is an aliphatic group having 1 to 3 carbon atoms, a cycloaliphatic group having 3 to 8 carbon atoms, and a cycloaliphatic group having 4 to 20 carbon atoms. It is an aromatic group, an araliphatic group (aralkyl group), or a heteroaromatic group, and any of them may have a substituent. Among the above groups, the main ones include acetyl group, propionyl group, phenylacetyl group, phenoxyacetyl group, optically active or racemic α-phenylpropionyl group, benzoyl group, naphthoyl group, and aromatic ring groups thereof. having one or more substituents such as methyl, chlorphenyl, etc.
Methylcarbamoyl group, phenylcarbamoyl group, naphthylcarbamoyl group, hensylcarbamoyl group, naphthylmethylcarbamoyl group, optically active or racemic α-phenylethyl group, α-naphthylethyl group, and methyl, chlor, or phenyl on their aromatic rings. Those having one or more other tags, benzyl groups, naphthylmethyl groups, and those having one or more substituents such as methyl, chloro, phenyl, etc. on their aromatic rings;
Examples include methyl group, ethyl group, propyl group, 2-hydroxyethyl group, 2-hydroxy-2-methylpropyl group, and optically active or racemic 2-hydroxypropyl group.
これらの原子団は一種であっても、複数種であっても良
く、またこれらの原子団以外に、該多糖誘導体に可塑性
や1.不揮発性も賦与するために、分子N100乃至1
000の高分子量の原子団を結合しても良い。These atomic groups may be one type or multiple types, and in addition to these atomic groups, the polysaccharide derivative has plasticity and 1. In order to impart non-volatility, the molecule N100 to 1
000 high molecular weight atomic groups may be combined.
これらの多糖誘導体は公知の各種の化学反応を用いて容
易に得ることができる。これら多糖及びその誘導体は原
料の入手し易さ、安定性などの故に工業的なりロマトグ
ラフィー分離には特に適したものである。These polysaccharide derivatives can be easily obtained using various known chemical reactions. These polysaccharides and their derivatives are particularly suitable for industrial chromatographic separation because of their ease of raw material availability and stability.
本発明の分離法は、これら多1i誘導体の中から、分離
しようとする化合物、分離の方法によって適当なものを
選べば良い。In the separation method of the present invention, an appropriate one may be selected from among these multi-1i derivatives depending on the compound to be separated and the separation method.
多糖誘導体を有効成分とする分離剤は、その−次構造が
同一であっても、分子量や、成形のために溶媒を用いた
場合にはその溶媒の種類、熱処理、溶媒による膨潤、液
晶形成等によって分離性は変化する。また、クロマトグ
ラフィーにおいて分離の程度を高めるには、クロマトグ
ラフィー用分離剤のいわゆる理論段高さを小さくするこ
とが必要であり、そのための様々な実施態様が可能であ
る。例えば液体クロマトグラフィー或いは薄層クロマト
グラフィーでの分離においては、カラム理論段高さは、
分離剤粒子の形状、大きさ、微細構造等によって著しく
変化する。例えば、粒子径は大きいものより小さいもの
、粒子径分布は大きいものより小さいもの、粒子形状は
無定形よりも球状、緻密粒子よりは多孔質粒子あるいは
表面のみに多tR誘導体の吸着活性層を有するもの等が
好ましい。また分離剤の理論段高さや、機械的強度、操
作性、耐溶剤性を改善するために、無機あるいは有機物
あるいは両者より成る担体上に該多糖誘導体を物理的に
あるいは化学結合によって担持することもある。また該
多糖誘導体の熱的安定性を改善したり、可塑性を与えて
理論段高さを上げるなどの目的で、該多糖誘導体にこれ
以外の添加物を加えることもある。Separating agents containing polysaccharide derivatives as active ingredients, even if their secondary structures are the same, have different molecular weights, types of solvents used for molding, heat treatment, swelling by solvents, liquid crystal formation, etc. The separability changes depending on the Furthermore, in order to increase the degree of separation in chromatography, it is necessary to reduce the so-called theoretical plate height of the separating agent for chromatography, and various embodiments for this purpose are possible. For example, in liquid chromatography or thin layer chromatography separation, the column theoretical plate height is
It varies significantly depending on the shape, size, fine structure, etc. of the separating agent particles. For example, the particle size is smaller than larger, the particle size distribution is smaller than larger, the particle shape is more spherical than amorphous, porous particles are more porous than dense particles, or there is an active layer for adsorption of multi-tR derivatives only on the surface. Preferably. In addition, in order to improve the theoretical plate height, mechanical strength, operability, and solvent resistance of the separation agent, the polysaccharide derivative may be supported physically or by chemical bonding on a carrier made of an inorganic or organic material or both. be. In addition, other additives may be added to the polysaccharide derivative for the purpose of improving the thermal stability of the polysaccharide derivative, or imparting plasticity to increase the theoretical plate height.
クロマトグラフィー分離の手法としては、液体クロマト
グラフィー、薄層クロマトグラフィー、ガスクロマトグ
ラフィー等が代表的なものである。分離剤の形状は各々
の手法にとって適切なものを選べば良い。Typical chromatographic separation techniques include liquid chromatography, thin layer chromatography, and gas chromatography. The shape of the separating agent may be selected appropriately for each method.
分離剤が異なった物質を識別する能力そのもの(分離係
数αの大きさで示される)は、その分離剤の吸着活性成
分の化学的性質によって決まる。蔓において多糖誘導体
より成る分離剤がステロイド骨格を有する化合物の分離
においてシリカゲルやODSなどの一般的な分離剤に比
べて、多くの場合に高いα値を示すことが本発明の最も
重要な意味である。しかし、多IPi誘導体を用いるこ
との長所はそれだけではなく、例えば化合物間の溶出順
序、試料負荷量、液体及び薄層クロマトグラフィーの場
合には適当な保持の強さを与える移動相の種類などの緒
特性においても、しばしば他充填とは異なった特徴を示
し、これらも本発明の分離方法の長所となり得る。ステ
ロイド骨格を有する化合物の分離において、多糖誘導体
を有効成分とする分離剤が示す上記の特徴は、該多糖誘
導体と分離対象とする物質との化学的相互作用に基づく
ものであって、前記した実施態様のいかなるバリエーシ
ョンにおいても共通に認められることは容易に類推でき
る。従って、本発明は、多糖誘導体を有効成分とする分
離剤を用いる限り、そのいかなる実施態様をも含むもの
である。The ability of a separating agent to discriminate between different substances (indicated by the magnitude of the separation coefficient α) itself is determined by the chemical properties of the adsorbing active component of the separating agent. The most important aspect of the present invention is that separation agents made of polysaccharide derivatives often exhibit higher α values than general separation agents such as silica gel and ODS in separating compounds with steroid skeletons. be. However, the advantages of using multi-IPi derivatives are not limited to this, for example, the elution order between compounds, sample loading, and in the case of liquid and thin layer chromatography, the type of mobile phase that provides suitable retention strength. In terms of organic properties, they often exhibit characteristics that are different from those of other packings, and these can also be an advantage of the separation method of the present invention. In the separation of compounds having steroid skeletons, the above-mentioned characteristics exhibited by separation agents containing polysaccharide derivatives as active ingredients are based on the chemical interaction between the polysaccharide derivatives and the substance to be separated. What is common in any variation of the embodiments can be easily deduced by analogy. Therefore, the present invention includes any embodiment thereof as long as a separation agent containing a polysaccharide derivative as an active ingredient is used.
本発明で用いる多Pi誘導体がステロイド骨格を有する
化合物の分離に有効である理由は完全に明らかにはなっ
ていない。しかし現在までに行った諸研究の結果では、
多糖誘導体において多糖を修飾する置換基は、分離対象
となるステロイド化合物と双極子相互作用、π−π重な
り相互作用、水素結合等の機構で会合することが判明し
ている。糖残基の骨格は、その環状構造、多数の置換基
の存在などによりコンホメーションが制限されているこ
とが特徴であり、また残基と残基の並び方も一般に規則
正しい。このような多糖骨格に結合した置換基は、規則
正しい配列をなし、特定の立体的形状を持つ吸着場を形
成する。このように吸着場の形が定まっていることは、
シリカゲルやODSなどの無定形物質と本質的に異なる
点である。これが、分離対象化合物の吸着基周辺の化学
的環境、特に立体化学的環境に対する高い識別能力をも
たらす要因であると考えられる。The reason why the multi-Pi derivative used in the present invention is effective in separating compounds having a steroid skeleton is not completely clear. However, according to the results of various studies conducted to date,
It has been found that a substituent that modifies a polysaccharide in a polysaccharide derivative associates with the steroid compound to be separated through mechanisms such as dipolar interaction, π-π overlap interaction, and hydrogen bonding. The skeleton of sugar residues is characterized by restricted conformation due to its cyclic structure and the presence of numerous substituents, and the arrangement of the residues is generally regular. The substituents bonded to such a polysaccharide skeleton form a regular arrangement and form an adsorption field with a specific three-dimensional shape. This fixed shape of the adsorption field means that
This is essentially different from amorphous substances such as silica gel and ODS. This is considered to be a factor that provides high discrimination ability for the chemical environment, especially the stereochemical environment, around the adsorption group of the compound to be separated.
本発明によって、ステロイド骨格を有する化合物の混合
物を分離する有効な手法が確立された。クロマトグラフ
ィー法による分離は、これに用いるカラムあるいは薄層
が小さければ分析の手段として便利であるが、単にカラ
ムあるいは薄層を大きくし、また試料量を増やすだけで
そのまま精製の目的にも用いることができる。The present invention has established an effective method for separating mixtures of compounds having steroid skeletons. Separation by chromatography is convenient as a means of analysis if the column or thin layer used is small, but it can also be used for purification purposes by simply increasing the size of the column or thin layer and increasing the amount of sample. I can do it.
かくして本発明の分離法は、各種ステロイド化合物の分
析及び分離精製の手段を提供し、ひいては生理学的研究
の進展や医薬の開発に貢献するものとなろう。Thus, the separation method of the present invention will provide a means for analyzing, separating and purifying various steroid compounds, and will ultimately contribute to the progress of physiological research and the development of medicines.
以下本発明を実施例及びシリカゲル、ODSによる比較
例を用いて具体的に説明するが、本発明がこれらの実施
例に限定されるものでないことは、既に述べた理由によ
り明白である。The present invention will be specifically explained below using examples and comparative examples using silica gel and ODS, but it is clear that the present invention is not limited to these examples for the reasons already stated.
以下の実施例では、多糖誘導体をシリカゲル上に担持し
た分離剤を用いた分離カラム(ダイセル化学工業■、C
IIIRALにEL O或いはCHIRAl、r’AK
A)を用いた。また比較例としては、シリカゲルを用い
た分離力°ラム(ダイセル化学工業■、DC−PAK
S (Si 5−100))及びシリカゲルにオクタデ
シル基を結合したいわゆるODS固定相を用いた分離カ
ラム(ガスクロ工業■、Inertsil 0DS)で
の同じ混合物の分離を例示した。In the following examples, a separation column (Daicel Chemical Industry ■, C
IIIRAL to EL O or CHIRAL, r'AK
A) was used. In addition, as a comparative example, separation power °lum using silica gel (Daicel Chemical Industry ■, DC-PAK
The separation of the same mixture on a separation column (Gascro Kogyo ■, Inertsil 0DS) using a so-called ODS stationary phase in which octadecyl groups are bonded to S (Si 5-100)) and silica gel is illustrated.
以下、実施例及び比較例中で用いられるパラメーターα
は以下のように定義される。Below, the parameter α used in Examples and Comparative Examples
is defined as below.
実施例1
5α−アントロスタン−3,17−ジオン(5α−an
drostan−3+17−dione) (1)及び
5β−アントロスタン−3,17−ジオン(5β−an
dros tan−3,17−dione ) (2)
(共にSIGMA CHEMICAL Co。Example 1 5α-antrostane-3,17-dione (5α-an
drostan-3+17-dione) (1) and 5β-antrostane-3,17-dione (5β-an
drostan-3,17-dione) (2)
(Both SIGMA CHEMICAL Co.
製)ヲセルローストリス(4−メチルヘンシェード)よ
り成る分離カラムCl1rRALCEL OJを用いて
分離した。クロマトグラフィー条件、両異性体の保持時
間、容量比、分離係数及び溶離順位を表1に示した。Separation was performed using a separation column Cl1rRALCEL OJ made of cellulose tris (4-methylhenshade) (manufactured by Co., Ltd.). The chromatography conditions, retention times, volume ratios, separation coefficients, and elution orders of both isomers are shown in Table 1.
比較例1
実施例1と同し混合物をシリカゲル及びODSを用いた
カラムで分離した。りaマドグラフィー条件、両異性体
1. (2))の保持時間、容量比、分離係数及び溶離
順位を表1に示した。Comparative Example 1 The same mixture as in Example 1 was separated using a column using silica gel and ODS. Ria madography conditions, both isomers 1. The retention time, volume ratio, separation coefficient, and elution order of (2)) are shown in Table 1.
表 1
実施例2
5α−アントロスタン−3,17−ジオン(5α−an
drostan−3+17−dione) (1)及び
5α−アントロスタン−1−エン−3,17−ジオン(
5α−androstan −1−en−3,17−d
ione ) (3) (共にSIGMA CHEMI
CAL CO,製)をアミロース−トリス(3,5−ジ
メチルフェニルカルバメート)よりなる分離カラムCI
IIRALPAK ADを用いて分離した。Table 1 Example 2 5α-antrostane-3,17-dione (5α-an
drostan-3+17-dione) (1) and 5α-antrostan-1-ene-3,17-dione (
5α-androstan-1-en-3,17-d
ione) (3) (Both SIGMA CHEMI
(manufactured by CAL CO, Ltd.) using a separation column CI made of amylose-tris (3,5-dimethylphenyl carbamate).
Separated using IIRALPAK AD.
クロマトグラフィー条件、両化合物の保持時間、容量比
、分離係数及び溶離順位を表2に示した。The chromatography conditions, retention times, volume ratios, separation coefficients, and elution orders of both compounds are shown in Table 2.
比較例2
実施例2と同じ混合物をシリカゲル及びODSを用いて
カラムで分離した。クロマトグラフィー条件、両化合物
1. (3))を保持時間、容量比、分離係数を表2に
示した。Comparative Example 2 The same mixture as in Example 2 was separated on a column using silica gel and ODS. Chromatography conditions, both compounds 1. (3)) The retention time, capacity ratio, and separation coefficient are shown in Table 2.
表 2
実施例3
ヒトtllルチゾン(hydrocortisone)
(4) (SIGMACIIEMICAL Co、製
)及びプレドニゾロン(pred−nisolone)
(5) (東京化成株式会社製)をアミロース−トリ
ス(3,5−ジメチルフェニルカルバメート)よりなる
分離カラム(JIIRALCEL ADを用いて分離し
た。クロマトグラフィー条件、両化合物の保持時間、容
量比、分離係数及び溶離順位を表3に示した。Table 2 Example 3 Human tll lutisone (hydrocortisone)
(4) (manufactured by SIGMACII EMICAL Co.) and prednisolone (pred-nisolone)
(5) (manufactured by Tokyo Kasei Co., Ltd.) was separated using a separation column (JIIRALCEL AD) made of amylose-tris (3,5-dimethylphenylcarbamate). Chromatography conditions, retention time of both compounds, volume ratio, separation The coefficients and elution ranks are shown in Table 3.
比較例3
実施例3と同じ混合物をシリカゲル及びOOSを用いた
カラムで分離した。クロマlルブラフィー条件、両化合
物((4)、 (5))の保持時間、容量比、分離係数
及び溶離順位を表3に示した。Comparative Example 3 The same mixture as in Example 3 was separated on a column using silica gel and OOS. Table 3 shows the chromal lubrication conditions, retention time, volume ratio, separation coefficient, and elution order of both compounds ((4), (5)).
表 3
実施例4
5α−アントロスタン−3−オン(5α−andros
tan −3−one) (6)及び5α−アンドロス
タン−17−オン(5a −andros tane−
17−one)(7)(共にSIGM八CIへEMIC
AL Co、製)をセルローストリス(3,5−ジメチ
ルフェニルカルバメート)よりなる分離カラムCIII
RALC[L OD及び実施例2及び3で用いた分離カ
ラムCHIRALr’AK ADを用いて分離した。ク
ロマトグラフィー条件、両化合物の保持時間、容量比、
分離係数及び溶離順位を表4に示した。Table 3 Example 4 5α-Anthrostan-3-one (5α-andros
tan-3-one) (6) and 5α-androstane-17-one (5a-androstane-
17-one) (7) (Both EMIC to SIGM 8CI
(manufactured by AL Co.) was separated into a separation column CIII made of cellulose tris (3,5-dimethylphenyl carbamate).
Separation was performed using RALC [L OD and the separation column CHIRALr'AK AD used in Examples 2 and 3. Chromatography conditions, retention time of both compounds, volume ratio,
The separation coefficient and elution order are shown in Table 4.
比較例4
実施例4と同じ混合物をシリカゲル及びODSを用いた
カラムで分離した。クロマトグラフィー条件、両化合物
の保持時間、容量比、分離係数及び溶離順位を表4に示
した。Comparative Example 4 The same mixture as in Example 4 was separated on a column using silica gel and ODS. Table 4 shows the chromatography conditions, retention time, volume ratio, separation coefficient, and elution order of both compounds.
表 4Table 4
Claims (1)
、多糖誘導体を有効成分とする分離剤を用いることを特
徴とするステロイド化合物の分離法。1. A method for separating steroid compounds, the method comprising using a separating agent containing a polysaccharide derivative as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2278614A JP2837531B2 (en) | 1990-10-16 | 1990-10-16 | Separation of steroid compounds |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2278614A JP2837531B2 (en) | 1990-10-16 | 1990-10-16 | Separation of steroid compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH04154795A true JPH04154795A (en) | 1992-05-27 |
JP2837531B2 JP2837531B2 (en) | 1998-12-16 |
Family
ID=17599736
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2278614A Expired - Fee Related JP2837531B2 (en) | 1990-10-16 | 1990-10-16 | Separation of steroid compounds |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2837531B2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6107492A (en) * | 1998-05-08 | 2000-08-22 | Ucb, S.A. | Process for the preparation of levetiracetam |
CN111948302A (en) * | 2020-06-29 | 2020-11-17 | 中国农业科学院茶叶研究所 | Resolution preparation method of fluorothiazole pyrithylone enantiomer |
-
1990
- 1990-10-16 JP JP2278614A patent/JP2837531B2/en not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6107492A (en) * | 1998-05-08 | 2000-08-22 | Ucb, S.A. | Process for the preparation of levetiracetam |
CN111948302A (en) * | 2020-06-29 | 2020-11-17 | 中国农业科学院茶叶研究所 | Resolution preparation method of fluorothiazole pyrithylone enantiomer |
Also Published As
Publication number | Publication date |
---|---|
JP2837531B2 (en) | 1998-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pirkle et al. | Design, synthesis, and evaluation of an improved enantioselective naproxen selector | |
US5202433A (en) | Polysaccharide derivatives as separating agents | |
JPS60226830A (en) | Separating agent consisting of 1,3-glucan | |
JPH04154795A (en) | Separation of steroid compound | |
JPS61267537A (en) | Optical resolution of oxycyclopentenone and derivative thereof | |
CA2465043C (en) | Novel mandelate salts of substituted tetracyclic tetrahydrofuran derivatives | |
JP6016631B2 (en) | Separating agent for optical isomers | |
JPWO2002070123A1 (en) | Separating agent for optical isomers | |
JPH05163164A (en) | Separation agent | |
JPH06211902A (en) | Substituted aromatic carbamate derivative of polysaccharide, and separating agent | |
JPS60226833A (en) | Separating agent consisting of aromatic ester derivative of polysaccharide | |
JPH07113026B2 (en) | Method of optical resolution of ofloxacin esters | |
JP2009084275A (en) | Method for producing ursodeoxycholic acid | |
JP2669554B2 (en) | Novel polysaccharide derivatives and separating agents | |
JP5675034B2 (en) | Neutral lipid absorption inhibitor and saponin compound obtained from daisy and use thereof | |
JP2006506420A (en) | Pharmaceutically useful new dower pheromone compounds for aging and stress regulation and methods for their separation and purification | |
US20040065608A1 (en) | Separatory agent comprising polysacciiaride derivative having polycyclic structure | |
JP2708466B2 (en) | Optical splitting method | |
JPS61176538A (en) | Optical resolution of aralkyl alcohol | |
JPH0513157B2 (en) | ||
JPS6330444A (en) | Direct optical resolution of acetoin derivative | |
JPS62198657A (en) | Optical resolution of sulfoxide | |
JPH0769882A (en) | Agent for suppressing activation of epstein-barr virus | |
JPS62230740A (en) | Production of optically active 4-hydroxy-1(e)-iodooct-1-ene | |
JPH03181433A (en) | Direct resolution for 1-p-substituted phenylethanol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313532 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
LAPS | Cancellation because of no payment of annual fees |